J. Michael White
Research Subjects
J. Michael White has a total of 307 co-authors. Here are the top co-authors by number of shared publications:
Cora D. Arthur
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, USA
5 shared publicationsRobert D Schreiber
5 shared publicationsRobert D. Schreiber
5 shared publications- Robert D. Schreiber
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
5 shared publications - Robert D. Schreiber
Department of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, USA
5 shared publications - Hussein Sultan
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells
It is well established that CD4+ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8+ T-cell priming has been well investigated, their requirement at the effector phase in the tumor is only now beginning to be appreciated. Herein, we used our major histocompatibility complex class II–negative (MHC-II−) sarcoma models to confirm that CD4+ T cells are essential not only during T-cell priming but also to maintain T-cell effector function within the tumor. Depleting CD4+ T cells at the effector phase, after CD8+ T-cell priming had occurred, abolished ICT-induced tumor rejection despite the detection of tumor-specific CD8+ T cells and their intratumoral accumulation. CD4+ T cells were required for functional reinvigoration of CD8+ tumor-infiltrating lymphocytes by ICT, leading to enhanced cytokine production, expression of cytotoxicity, and reduced exhaustion—without affecting CD8+ T-cell proliferation. Mechanistically, CD4+ T-cell function at the effector phase did not require CD40/CD40L signaling, which is necessary for efficient priming but rather depended on IL2 and IFNγ. Using a T-cell receptor–mimic monoclonal antibody (1G10) specific for the dominant neoantigen:I-Ab complex on antigen-presenting cells formed during T3 sarcoma challenge, we further showed that ongoing MHC-II neoantigen presentation was necessary to sustain CD4+ T-cell help after priming. These findings reveal temporally distinct requirements for CD4+ T-cell help and establish a need for continuous CD4+/CD8+ T-cell cooperation as a prerequisite for anti–PD-1/anti–CTLA-4 ICT efficacy against MHC-II− tumors.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells
It is well established that CD4+ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8+ T-cell priming has been well investigated, their requirement at the effector phase in the tumor is only now beginning to be appreciated. Herein, we used our major histocompatibility complex class II–negative (MHC-II−) sarcoma models to confirm that CD4+ T cells are essential not only during T-cell priming but also to maintain T-cell effector function within the tumor. Depleting CD4+ T cells at the effector phase, after CD8+ T-cell priming had occurred, abolished ICT-induced tumor rejection despite the detection of tumor-specific CD8+ T cells and their intratumoral accumulation. CD4+ T cells were required for functional reinvigoration of CD8+ tumor-infiltrating lymphocytes by ICT, leading to enhanced cytokine production, expression of cytotoxicity, and reduced exhaustion—without affecting CD8+ T-cell proliferation. Mechanistically, CD4+ T-cell function at the effector phase did not require CD40/CD40L signaling, which is necessary for efficient priming but rather depended on IL2 and IFNγ. Using a T-cell receptor–mimic monoclonal antibody (1G10) specific for the dominant neoantigen:I-Ab complex on antigen-presenting cells formed during T3 sarcoma challenge, we further showed that ongoing MHC-II neoantigen presentation was necessary to sustain CD4+ T-cell help after priming. These findings reveal temporally distinct requirements for CD4+ T-cell help and establish a need for continuous CD4+/CD8+ T-cell cooperation as a prerequisite for anti–PD-1/anti–CTLA-4 ICT efficacy against MHC-II− tumors.
- 16 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1604-1619
CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells
It is well established that CD4+ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8+ T-cell priming has been well investigated, their requirement at the effector phase in the tumor is only now beginning to be appreciated. Herein, we used our major histocompatibility complex class II–negative (MHC-II−) sarcoma models to confirm that CD4+ T cells are essential not only during T-cell priming but also to maintain T-cell effector function within the tumor. Depleting CD4+ T cells at the effector phase, after CD8+ T-cell priming had occurred, abolished ICT-induced tumor rejection despite the detection of tumor-specific CD8+ T cells and their intratumoral accumulation. CD4+ T cells were required for functional reinvigoration of CD8+ tumor-infiltrating lymphocytes by ICT, leading to enhanced cytokine production, expression of cytotoxicity, and reduced exhaustion—without affecting CD8+ T-cell proliferation. Mechanistically, CD4+ T-cell function at the effector phase did not require CD40/CD40L signaling, which is necessary for efficient priming but rather depended on IL2 and IFNγ. Using a T-cell receptor–mimic monoclonal antibody (1G10) specific for the dominant neoantigen:I-Ab complex on antigen-presenting cells formed during T3 sarcoma challenge, we further showed that ongoing MHC-II neoantigen presentation was necessary to sustain CD4+ T-cell help after priming. These findings reveal temporally distinct requirements for CD4+ T-cell help and establish a need for continuous CD4+/CD8+ T-cell cooperation as a prerequisite for anti–PD-1/anti–CTLA-4 ICT efficacy against MHC-II− tumors.
- 16 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1604-1619
CD4+ T Cells Play Distinct Roles during the Priming versus Effector Phases of Immune Checkpoint Therapy–Dependent Tumor Elimination by CD8+ T Cells
It is well established that CD4+ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8+ T-cell priming has been well investigated, their requirement at the effector phase in the tumor is only now beginning to be appreciated. Herein, we used our major histocompatibility complex class II–negative (MHC-II−) sarcoma models to confirm that CD4+ T cells are essential not only during T-cell priming but also to maintain T-cell effector function within the tumor. Depleting CD4+ T cells at the effector phase, after CD8+ T-cell priming had occurred, abolished ICT-induced tumor rejection despite the detection of tumor-specific CD8+ T cells and their intratumoral accumulation. CD4+ T cells were required for functional reinvigoration of CD8+ tumor-infiltrating lymphocytes by ICT, leading to enhanced cytokine production, expression of cytotoxicity, and reduced exhaustion—without affecting CD8+ T-cell proliferation. Mechanistically, CD4+ T-cell function at the effector phase did not require CD40/CD40L signaling, which is necessary for efficient priming but rather depended on IL2 and IFNγ. Using a T-cell receptor–mimic monoclonal antibody (1G10) specific for the dominant neoantigen:I-Ab complex on antigen-presenting cells formed during T3 sarcoma challenge, we further showed that ongoing MHC-II neoantigen presentation was necessary to sustain CD4+ T-cell help after priming. These findings reveal temporally distinct requirements for CD4+ T-cell help and establish a need for continuous CD4+/CD8+ T-cell cooperation as a prerequisite for anti–PD-1/anti–CTLA-4 ICT efficacy against MHC-II− tumors.
- Open Access
- 1 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (1) , 61-72
Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3
MLL rearrangements (MLLrs) are the most common cause of congenital and infant leukemias. MLLrs arise prior to birth and can transform fetal/neonatal progenitors with the help of only a few additional cooperating mutations. Despite the low threshold for transformation, infant leukemias are rare, and congenital leukemias, which arise before birth, are even less common. These observations raise the question of whether mechanisms exist to suppress leukemic transformation during fetal life, thereby protecting the developing fetus from malignancy during a period of rapid hematopoietic progenitor expansion. To test this possibility, we used a mouse model of temporally controlled MLL::ENL expression to show that fetal MLL::ENL exposure establishes a heritable, leukemia-resistant state within hematopoietic progenitors that persists after birth. When we induced MLL::ENL expression prior to birth and transplanted hematopoietic stem and progenitor cells, very few recipient mice developed acute myeloid leukemia (AML) despite robust engraftment. When we induced MLL::ENL expression shortly after birth, all recipient mice developed a highly penetrant AML. Fetal MLL::ENL expression imposed a negative selective pressure on hematopoietic progenitors before birth followed by loss of self-renewal gene expression and enhanced myeloid differentiation after birth that precluded transformation. These changes did not occur when MLL::ENL expression initiated shortly after birth. The fetal barrier to transformation was enforced by the histone methyltransferase MLL3, and it could be overcome by cooperating mutations, such as NrasG12D. Heritable fetal protection against leukemic transformation may contribute to the low incidence of congenital and infant leukemias in humans.
- 1 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (1) , 61-72
Open AccessFetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3
MLL rearrangements (MLLrs) are the most common cause of congenital and infant leukemias. MLLrs arise prior to birth and can transform fetal/neonatal progenitors with the help of only a few additional cooperating mutations. Despite the low threshold for transformation, infant leukemias are rare, and congenital leukemias, which arise before birth, are even less common. These observations raise the question of whether mechanisms exist to suppress leukemic transformation during fetal life, thereby protecting the developing fetus from malignancy during a period of rapid hematopoietic progenitor expansion. To test this possibility, we used a mouse model of temporally controlled MLL::ENL expression to show that fetal MLL::ENL exposure establishes a heritable, leukemia-resistant state within hematopoietic progenitors that persists after birth. When we induced MLL::ENL expression prior to birth and transplanted hematopoietic stem and progenitor cells, very few recipient mice developed acute myeloid leukemia (AML) despite robust engraftment. When we induced MLL::ENL expression shortly after birth, all recipient mice developed a highly penetrant AML. Fetal MLL::ENL expression imposed a negative selective pressure on hematopoietic progenitors before birth followed by loss of self-renewal gene expression and enhanced myeloid differentiation after birth that precluded transformation. These changes did not occur when MLL::ENL expression initiated shortly after birth. The fetal barrier to transformation was enforced by the histone methyltransferase MLL3, and it could be overcome by cooperating mutations, such as NrasG12D. Heritable fetal protection against leukemic transformation may contribute to the low incidence of congenital and infant leukemias in humans.
- Open Access
- 24 July 2024
- Published by Springer Nature in Nature
- Vol. 632 (8023) , 182-191
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
CD4+ T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses1–5, other CD4+ T cells have recently been implicated in inhibiting this response6,7. Yet, the nature and function of the latter remain unclear. Here, using vaccines containing MHC class I (MHC-I) neoantigens (neoAgs) and different doses of tumour-derived MHC-II neoAgs, we discovered that whereas the inclusion of vaccines with low doses of MHC-II-restricted peptides (LDVax) promoted tumour rejection, vaccines containing high doses of the same MHC-II neoAgs (HDVax) inhibited rejection. Characterization of the inhibitory cells induced by HDVax identified them as type 1 regulatory T (Tr1) cells expressing IL-10, granzyme B, perforin, CCL5 and LILRB4. Tumour-specific Tr1 cells suppressed tumour rejection induced by anti-PD1, LDVax or adoptively transferred tumour-specific effector T cells. Mechanistically, HDVax-induced Tr1 cells selectively killed MHC-II tumour antigen-presenting type 1 conventional dendritic cells (cDC1s), leading to low numbers of cDC1s in tumours. We then documented modalities to overcome this inhibition, specifically via anti-LILRB4 blockade, using a CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes. Collectively, these data show that cytotoxic Tr1 cells, which maintain peripheral tolerance, also inhibit antitumour responses and thereby function to impede immune control of cancer.
- 24 July 2024
- Published by Springer Nature in Nature
- Vol. 632 (8023) , 182-191
Open AccessNeoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
CD4+ T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses1–5, other CD4+ T cells have recently been implicated in inhibiting this response6,7. Yet, the nature and function of the latter remain unclear. Here, using vaccines containing MHC class I (MHC-I) neoantigens (neoAgs) and different doses of tumour-derived MHC-II neoAgs, we discovered that whereas the inclusion of vaccines with low doses of MHC-II-restricted peptides (LDVax) promoted tumour rejection, vaccines containing high doses of the same MHC-II neoAgs (HDVax) inhibited rejection. Characterization of the inhibitory cells induced by HDVax identified them as type 1 regulatory T (Tr1) cells expressing IL-10, granzyme B, perforin, CCL5 and LILRB4. Tumour-specific Tr1 cells suppressed tumour rejection induced by anti-PD1, LDVax or adoptively transferred tumour-specific effector T cells. Mechanistically, HDVax-induced Tr1 cells selectively killed MHC-II tumour antigen-presenting type 1 conventional dendritic cells (cDC1s), leading to low numbers of cDC1s in tumours. We then documented modalities to overcome this inhibition, specifically via anti-LILRB4 blockade, using a CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes. Collectively, these data show that cytotoxic Tr1 cells, which maintain peripheral tolerance, also inhibit antitumour responses and thereby function to impede immune control of cancer.
- Open Access
- 23 July 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (9)
Fetal MAVS and type I IFN signaling pathways control ZIKV infection in the placenta and maternal decidua
The contribution of placental immune responses to congenital Zika virus (ZIKV) syndrome remains poorly understood. Here, we leveraged a mouse model of ZIKV infection to identify mechanisms of innate immune restriction exclusively in the fetal compartment of the placenta. ZIKV principally infected mononuclear trophoblasts in the junctional zone, which was limited by mitochondrial antiviral-signaling protein (MAVS) and type I interferon (IFN) signaling mechanisms. Single nuclear RNA sequencing revealed MAVS-dependent expression of IFN-stimulated genes (ISGs) in spongiotrophoblasts but not in other placental cells that use alternate pathways to induce ISGs. ZIKV infection of Ifnar1−/− or Mavs−/− placentas was associated with greater infection of the adjacent immunocompetent decidua, and heterozygous Mavs+/− or Ifnar1+/− dams carrying immunodeficient fetuses sustained greater maternal viremia and tissue infection than dams carrying wild-type fetuses. Thus, MAVS-IFN signaling in the fetus restricts ZIKV infection in junctional zone trophoblasts, which modulates dissemination and outcome for both the fetus and the pregnant mother.
- 23 July 2024
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (9)
Open AccessFetal MAVS and type I IFN signaling pathways control ZIKV infection in the placenta and maternal decidua
The contribution of placental immune responses to congenital Zika virus (ZIKV) syndrome remains poorly understood. Here, we leveraged a mouse model of ZIKV infection to identify mechanisms of innate immune restriction exclusively in the fetal compartment of the placenta. ZIKV principally infected mononuclear trophoblasts in the junctional zone, which was limited by mitochondrial antiviral-signaling protein (MAVS) and type I interferon (IFN) signaling mechanisms. Single nuclear RNA sequencing revealed MAVS-dependent expression of IFN-stimulated genes (ISGs) in spongiotrophoblasts but not in other placental cells that use alternate pathways to induce ISGs. ZIKV infection of Ifnar1−/− or Mavs−/− placentas was associated with greater infection of the adjacent immunocompetent decidua, and heterozygous Mavs+/− or Ifnar1+/− dams carrying immunodeficient fetuses sustained greater maternal viremia and tissue infection than dams carrying wild-type fetuses. Thus, MAVS-IFN signaling in the fetus restricts ZIKV infection in junctional zone trophoblasts, which modulates dissemination and outcome for both the fetus and the pregnant mother.
- Open Access
- 14 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (28) , eadh2264
Lrp1 is essential for lethal Rift Valley fever hepatic disease in mice
Rift Valley fever virus (RVFV) is an emerging arbovirus found in Africa. While RVFV is pantropic and infects many cells and tissues, viral replication and necrosis within the liver play a critical role in mediating severe disease. The low-density lipoprotein receptor–related protein 1 (Lrp1) is a recently identified host factor for cellular entry and infection by RVFV. The biological significance of Lrp1, including its role in hepatic disease in vivo, however, remains to be determined. Because Lrp1 has a high expression level in hepatocytes, we developed a mouse model in which Lrp1 is specifically deleted in hepatocytes to test how the absence of liver Lrp1 expression affects RVF pathogenesis. Mice lacking Lrp1 expression in hepatocytes showed minimal RVFV replication in the liver, longer time to death, and altered clinical signs toward neurological disease. In contrast, RVFV infection levels in other tissues showed no difference between the two genotypes. Therefore, Lrp1 is essential for RVF hepatic disease in mice.
- 14 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (28) , eadh2264
Open AccessLrp1 is essential for lethal Rift Valley fever hepatic disease in mice
Rift Valley fever virus (RVFV) is an emerging arbovirus found in Africa. While RVFV is pantropic and infects many cells and tissues, viral replication and necrosis within the liver play a critical role in mediating severe disease. The low-density lipoprotein receptor–related protein 1 (Lrp1) is a recently identified host factor for cellular entry and infection by RVFV. The biological significance of Lrp1, including its role in hepatic disease in vivo, however, remains to be determined. Because Lrp1 has a high expression level in hepatocytes, we developed a mouse model in which Lrp1 is specifically deleted in hepatocytes to test how the absence of liver Lrp1 expression affects RVF pathogenesis. Mice lacking Lrp1 expression in hepatocytes showed minimal RVFV replication in the liver, longer time to death, and altered clinical signs toward neurological disease. In contrast, RVFV infection levels in other tissues showed no difference between the two genotypes. Therefore, Lrp1 is essential for RVF hepatic disease in mice.
- 17 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6633) , 661-+
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for antitumor responses and effective immune checkpoint blockade (ICB) therapy. Here, we show that human CD1c + CD5 + DCs are reduced in melanoma-affected lymph nodes, with CD5 expression on DCs correlating with patient survival. Activating CD5 on DCs enhanced T cell priming and improved survival after ICB therapy. CD5 + DC numbers increased during ICB therapy, and low interleukin-6 (IL-6) concentrations promoted their de novo differentiation. Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5 hi T helper and CD8 + T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5 + DCs are an essential component of optimal ICB therapy.
- 17 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6633) , 661-+
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
The induction of proinflammatory T cells by dendritic cell (DC) subtypes is critical for antitumor responses and effective immune checkpoint blockade (ICB) therapy. Here, we show that human CD1c + CD5 + DCs are reduced in melanoma-affected lymph nodes, with CD5 expression on DCs correlating with patient survival. Activating CD5 on DCs enhanced T cell priming and improved survival after ICB therapy. CD5 + DC numbers increased during ICB therapy, and low interleukin-6 (IL-6) concentrations promoted their de novo differentiation. Mechanistically, CD5 expression by DCs was required to generate optimally protective CD5 hi T helper and CD8 + T cells; further, deletion of CD5 from T cells dampened tumor elimination in response to ICB therapy in vivo. Thus, CD5 + DCs are an essential component of optimal ICB therapy.
- Open Access
- 16 February 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (6) , 1467-1482
Age-Dependent Reduction in Asthmatic Pathology through Reprogramming of Postviral Inflammatory Responses
Asthma is a chronic disease of childhood, but for unknown reasons, disease activity sometimes subsides as children mature. In this study, we present clinical and animal model evidence suggesting that the age dependency of childhood asthma stems from an evolving host response to respiratory viral infection. Using clinical data, we show that societal suppression of respiratory virus transmission during coronavirus disease 2019 lockdown disrupted the traditional age gradient in pediatric asthma exacerbations, connecting the phenomenon of asthma remission to virus exposure. In mice, we show that asthmatic lung pathology triggered by Sendai virus (SeV) or influenza A virus is highly age-sensitive: robust in juvenile mice (4–6 wk old) but attenuated in mature mice (>3 mo old). Interestingly, allergen induction of the same asthmatic traits was less dependent on chronological age than viruses. Age-specific responses to SeV included a juvenile bias toward type 2 airway inflammation that emerged early in infection, whereas mature mice exhibited a more restricted bronchiolar distribution of infection that produced a distinct type 2 low inflammatory cytokine profile. In the basal state, aging produced changes to lung leukocyte burden, including the number and transcriptional landscape of alveolar macrophages (AMs). Importantly, depleting AMs in mature mice restored post-SeV pathology to juvenile levels. Thus, aging influences chronic outcomes of respiratory viral infection through regulation of the AM compartment and type 2 inflammatory responses to viruses. Our data provide insight into how asthma remission might develop in children.
- 16 February 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (6) , 1467-1482
Open AccessAge-Dependent Reduction in Asthmatic Pathology through Reprogramming of Postviral Inflammatory Responses
Asthma is a chronic disease of childhood, but for unknown reasons, disease activity sometimes subsides as children mature. In this study, we present clinical and animal model evidence suggesting that the age dependency of childhood asthma stems from an evolving host response to respiratory viral infection. Using clinical data, we show that societal suppression of respiratory virus transmission during coronavirus disease 2019 lockdown disrupted the traditional age gradient in pediatric asthma exacerbations, connecting the phenomenon of asthma remission to virus exposure. In mice, we show that asthmatic lung pathology triggered by Sendai virus (SeV) or influenza A virus is highly age-sensitive: robust in juvenile mice (4–6 wk old) but attenuated in mature mice (>3 mo old). Interestingly, allergen induction of the same asthmatic traits was less dependent on chronological age than viruses. Age-specific responses to SeV included a juvenile bias toward type 2 airway inflammation that emerged early in infection, whereas mature mice exhibited a more restricted bronchiolar distribution of infection that produced a distinct type 2 low inflammatory cytokine profile. In the basal state, aging produced changes to lung leukocyte burden, including the number and transcriptional landscape of alveolar macrophages (AMs). Importantly, depleting AMs in mature mice restored post-SeV pathology to juvenile levels. Thus, aging influences chronic outcomes of respiratory viral infection through regulation of the AM compartment and type 2 inflammatory responses to viruses. Our data provide insight into how asthma remission might develop in children.
- 7 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (24)
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
Significance: Immune checkpoint therapy (ICT) has led to durable responses in a subset of cancer patients. Generally, patients who respond to ICT bear tumors with high mutational burden. Radiation is used for treatment of many types of cancers and has been shown to induce new mutations in treated tumor cells and to synergistically facilitate ICT. However, these latter actions have largely been explained by radiation-induced tumor cell death and/or effects on the host. Herein, we show that noncurative irradiation induces mutations in tumor cells lacking neoantigens and that these de novo-generated neoantigens function as targets for CD8 + T cells, resulting in increased immunogenicity of nonimmunogenic tumor cells. This study thus identifies an additional mechanism that explains synergy between immunotherapy and radiation.
- 7 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (24)
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
Significance: Immune checkpoint therapy (ICT) has led to durable responses in a subset of cancer patients. Generally, patients who respond to ICT bear tumors with high mutational burden. Radiation is used for treatment of many types of cancers and has been shown to induce new mutations in treated tumor cells and to synergistically facilitate ICT. However, these latter actions have largely been explained by radiation-induced tumor cell death and/or effects on the host. Herein, we show that noncurative irradiation induces mutations in tumor cells lacking neoantigens and that these de novo-generated neoantigens function as targets for CD8 + T cells, resulting in increased immunogenicity of nonimmunogenic tumor cells. This study thus identifies an additional mechanism that explains synergy between immunotherapy and radiation.